uploads/2018/07/Emend.png

How Merck’s Oncology Drugs Have Performed

By

Updated

Emend revenue trends

In the second quarter of 2018, Merck’s (MRK) Emend generated revenues of $148.0 million compared to $143.0 million in the second quarter of 2017, which reflected ~3% year-over-year (or YoY) growth and ~18% growth sequentially. In Q2 2018, in the US and international markets (outside the US markets), Emend generated revenues of $89.0 million and $59.0 million, respectively, compared to $83.0 million and $60.0 million in Q2 2017.

In the first half of 2018, Emend reported revenues of $273.0 million, reflecting a ~1% YoY decline. Merck’s Emend generated revenues of $168.0 million and $105.0 million from sales in the US and international markets, respectively, in the first half of 2018.

Article continues below advertisement

Temodar revenue trends

In Q2 2018, Temodar generated revenues of $56.0 million compared to $65.0 million in Q2 2017, which reflected a ~14% YoY decline and a ~2% decline sequentially. In Q2 2018, Temodar generated revenues of $1.0 million and $54.0 million from sales in the US and international markets. In the first half of 2018, Temodar generated revenues of $113.0 million compared to $130.0 in the first half of 2017, reflecting a ~13% YoY decline.

Lynparza and Lenvima revenue trends

In the second quarter of 2018, Merck generated revenues of $44.0 million and $35.0 million from sales of Lynparza and Lenvima, respectively. In the first half of 2018, Merck generated revenues of $76.0 million from the sales of Lynparza and $35.0 million from the sales of Lenvima.

Recent developments

In July 2018, Merck’s and AstraZeneca’s (AZN) Lynparza received approval from Japan’s Pharmaceuticals and Medical Devices Agency for individuals with unresectable or recurrent BRCA mutated HER2 (human epidermal growth factor receptor 2) negative breast cancer who underwent chemotherapy previously.

In June 2018, Merck and AstraZeneca declared positive results from the phase 3 SOLO-1 trial of Lynparza. In the phase 3 SOLO-1 trial, Lynparza met its primary endpoint by demonstrating statistically significant and clinically meaningful improvement in PFS (progression-free survival) versus placebo therapy as first-line therapy for treatment of individuals with advanced ovarian cancer. The approval for label expansion of Merck and AstraZeneca’s Lynparza could significantly boost sales growth of the drug.

In the next article, we’ll discuss Merck’s oncology drug Keytruda in detail.

Advertisement

More From Market Realist